2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 237

Characterization of Peripheral Lymphocyte Phenotype in Patients with IgG4-Related Disease
Abstract Number: 238

Identifying Immunoglobulin G4-Related Disease in Archived Pathological Specimens
Abstract Number: 239

Malignancies in Korean Patients with Immunoglobulin G4-Related Disease
Abstract Number: 240

The Relationship Between Serum Cholinesterase, Number of Organ Involvement and Fibrotic Markers in Japanese Patients with IgG4-Related Disease
Abstract Number: 241

Analysis of 84 Patients with IgG4-Related Disease and Malignancy
Abstract Number: 242

Clinical and Laboratory Features of IgG4-Related Retroperitoneal Fibrosis/Periarteritis in Japan: Retrospective Multicenter Study of 99 Cases
Abstract Number: 243

Eosinophilic Angiocentric Fibrosis : A Mimic of Vasculitis in IgG4 Related Disease Spectrum
Abstract Number: 244

Leflunomide and Glucocorticoids Combination Therapy for the Induction and Maintenance of Remission in Patients with IgG4-Related Disease
Abstract Number: 245

Efficacy of Cyclophosphamide Therapy in Idiopathic Retroperitoneal Fibrosis in a Retrospective Monocentric Analysis
Abstract Number: 246

Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis
Abstract Number: 247

ANTI-Interleukin 1 Therapy in FMF Amyloidosis: A Single Center Experience
Abstract Number: 248

Disease Severity and High Attack Frequency Under Colchicine Treatment Is Associated with Increased Carotid Intima Media Thickness in FMF
Abstract Number: 249

MiR-204-3p Associates with an Increased Level of IL-6 in Familial Mediterranean Fever By Targeting the PIK3 Signaling Pathway
Abstract Number: 250

Application of the 2016 European Leage Against Rheumatism (EULAR) /American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) Classification Criteria of Macrophage Activation Syndrome in Patients with Adult Onset Still’s Disease
Abstract Number: 251

Persistent Pruritic Skin Lesions with Dyskeratotic Cells in Upper Layer of Epidermis Are Specific and Associated with High Levels of Serum IL-18 in Adult-Onset Still’s Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].